Abstract
Objective
This study aimed to investigate the risk of Alzheimer’s disease among patients with age-related macular degeneration and its association with confounding comorbidities.
Method
This was a population-based, retrospective cohort study. By accessing data from the National Health Insurance Research Database of Taiwan, we identified 10,578 patients aged 50–100 years who were newly diagnosed with age-related macular degeneration between 2000 and 2012 and 10,578 non- age-related macular degeneration individuals. The comorbidities assessed were osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, and chronic obstructive pulmonary disease.
Results
Patients with age-related macular degeneration had a 1.23-fold increased risk of their condition advancing to Alzheimer’s disease (aHR = 1.23, 95% CI = 1.04–1.46). The younger patients were diagnosed with age-related macular degeneration, the more likely patients got Alzheimer’s disease (50–64 age group: aHR = 1.97, 95% CI = 1.04–3.73; 65–79 age group: aHR = 1.27, 95% CI = 1.02–1.58; 80–100 age group: aHR = 1.06, 95% CI = 0.78–1.45). In addition, there were significantly higher risks of Alzheimer’s disease for patients with cirrhosis (aHR = 1.50, 95% CI = 1.09–2.06) in the age-related macular degeneration cohort than in the non-age-related macular degeneration cohort.
Conclusion
Patients with age-related macular degeneration may exhibit a higher risk of Alzheimer’s disease than people without age-related macular degeneration.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible cognitive impairment. AD is the most common cause of dementia in the elderly, with an estimated 44 million people having AD worldwide, and the prevalence is predicted to triple by 2050 [1]. The characteristic neuropathological change in AD is the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles in brain tissues [2, 3].
The exact etiology and pathogenesis of AD remain unclear. Over the past two decades, the amyloid cascade hypothesis has been one of the most acceptable theories [4, 5]. Aβ stems from a transmembrane protein of neuronal cells termed amyloid precursor protein (APP). Aβ is generated when APP is sequentially cleaved by β-secretase and γ-secretase [6, 7]. The production and clearance imbalance of Aβ results in abnormal Aβ deposition in the neuropil, which is considered the main cause of synaptic loss and neuronal cell death in AD [8, 9].
Age-related macular degeneration (AMD) is another neurodegenerative disease that mainly affects the aging population. The disease results in progressive central vision loss and is the fourth leading cause of blindness worldwide [10, 11]. The hallmark pathology of AMD is ocular drusen and extracellular deposits located between the retinal pigment epithelium (RPE) and Bruch’s membrane [12]. Similar to senile plaques in AD, Aβ is also an important constituent in drusen [13–15]. Previous study has demonstrated that the Aβ in drusen correlates with the location of photoreceptors and RPE cell degeneration [16]. Moreover, oxidative stress, neuroinflammation, and complement activation have been implicated in both AD and AMD [17–19]. AD and AMD share risk factors such as cigarette smoking and diabetes [20–23]. In addition, genetic studies have also noted that the apolipoprotein E (APOE) epsilon‑4 and cysteine proteinase inhibitor cystatin C gene (CST3) increase the risk for both disorders [24, 25].
Because of the similarity in pathologic features between AMD and AD, there has been an increasing interest in investigating the potential link between the two diseases in recent years. However, most studies on the association between AMD and AD have shown paradoxical results. Several publications have documented that AMD was associated with cognitive impairment and dementia [26–29]. On the contrary, an epidemiologic study reported that there was no significant increase of the risk of dementia and AD following AMD [30]. Most past studies contained small sample size or only adjusted for a few factors. Therefore, we used a national population-based dataset from Taiwan National Health Insurance to investigate the association between AMD and AD.
Methods
Data resource
The requirement for informed consent was waived by both the National Health Insurance (NHI) Administration and China Medical University Hospital Research Ethics Committee.
Taiwan adopted a single-payer NHI program in March 1995. It is mandatory for Taiwanese citizens to enroll in the program; the coverage rate of NHI is over 99 percent. We used the Longitudinal Health Insurance Database 2010 (LHID 2010), which contains the claims data of 1,000,000 beneficiaries randomly sampled from the National Health Insurance Research Database (NHIRD). No significant differences in age and sex were found between the LHID 2010 and the enrollees in the mother NHIRD. Patient demographic characteristics included encrypted identification numbers, sex, dates of birth and death, diagnostic data, and procedures. The diagnostic data were coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The accuracy of the diagnosis codes of common conditions in NHIRD has been validated [31–33]. This study was approved by China Medical University Hospital Research Ethics Committee.
Sample participant, outcome, and comorbidity
We included 10,578 individuals aged at 50–100 years who were newly diagnosed with AMD (ICD-9-CM code 362.50, 362.51, and 362.52) by certified ophthalmologists between 2000 and 2010 in the AMD group. The date of the first outpatient visits or inpatient visit for AMD was defined as index date. For comparison, each AMD patient was frequency matched with an individual without AMD based on gender, age (in 5-year bands), and index-year. The exclusion criteria was patients with a pre-existing diagnosis of AD (ICD-9-CM 331) in both AMD cohort and control cohort. All study subjects were followed up until the appearance of AD, death, withdrawal from the insurance program or the end of study period (December 31, 2013).
All included patients were followed from the index date until the occurrence of the endpoint, withdrawal from the NHI program, or the end of 2013. The potential comorbidities included osteoporosis (ICD-9-CM code 733), diabetes (ICD-9-CM code 250 and A181), cirrhosis (ICD-9-CM code 571 and A347), cerebrovascular disease (ICD-9-CM code 342.34, and 430–438), chronic kidney disease (ICD-9-CM code 403.11, 403.91, 404.12, 404.92, 585, 586, v42.0, v45.1, v56.0, and v56.8), hypertension (ICD-9-CM code 401–405, A260 and A269), hyperlipidemia (ICD-9-CM code 272), coronary artery disease (ICD-9-CM code 410–414), and chronic obstructive pulmonary disease (ICD-9-CM code 491, 492, 493, and 496).
Statistical analysis
Descriptive statistics of demographics and comorbidities were summarized by counts, percentages, averages, and standard deviations (SDs) for the AMD and non-case cohort. Chi-square and Wilcoxon rank-sum tests were used to examine the differences in the characteristic distributions between the two cohorts. The cumulative incidence for AD was estimated using Kaplan-Meier methods and significance of the difference between the AMD cohort and the non-case cohort were tested using log-rank test. The incidence rate was calculated as the number of events divided by the person-years during the follow-up. The univariate Cox proportional hazards model was used to compute the hazard ratio (HR) and the 95% confidence interval (CI) for AD in the AMD cohort when compared to the non-case cohort. And the multivariate Cox proportional hazards model with covariates of gender, age, and comorbidities was used to compute the adjusted hazard ratio (aHR) and the 95% CI for AD in the AMD cohort when compared to the non-case cohort. Data analysis in this study was performed using SAS statistical software (Version 9.4 for Windows; SAS Institute Inc., Cary, NC, USA), with statistical significance set at a p value < 0.05.
Results
Table 1 reveals the demographic characteristics and the prevalence of comorbidities in both cohorts. The mean ages in the AMD and non-AMD group were 70.5 (±9.54, standard deviation [SD]) and 70.4 (±9.60, SD) years old, respectively, with the mean follow-up time of 5.68 (±3.81, SD) and 5.48 (±3.84, SD) years. The presence of osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease and chronic obstructive pulmonary disease was significantly higher in patients with AMD than controls.
Table 1. Demographic characteristics and presence of comorbidities in patients with and without age-related macular degeneration (AMD).
| AMD (n = 10578) | Non-AMD (n = 10578) | p-Value* | |||
|---|---|---|---|---|---|
| n | % | N | % | ||
| Gender | >0.99 | ||||
| Male | 5208 | 49.2 | 5208 | 49.2 | |
| Female | 5370 | 50.8 | 5370 | 50.8 | |
| Age, years | >0.99 | ||||
| 50–64 | 3106 | 29.4 | 3106 | 29.4 | |
| 65–79 | 5661 | 53.5 | 5661 | 53.5 | |
| 80–100 | 1811 | 17.1 | 1811 | 17.1 | |
| mean(SD)† | 70.5 (9.54) | 70.4 (9.60) | 0.3120 | ||
| Comorbidity | |||||
| Osteoporosis | 2648 | 25.0 | 2092 | 19.8 | <0.0001 |
| Diabetes | 5028 | 47.5 | 3965 | 37.5 | <0.0001 |
| Cirrhosis | 4137 | 39.1 | 3220 | 30.4 | <0.0001 |
| Cerebrovascular disease | 2832 | 26.7 | 2363 | 22.3 | <0.0001 |
| Chronic kidney disease | 736 | 6.96 | 560 | 5.29 | <0.0001 |
| Hypertension | 7557 | 71.4 | 6693 | 63.3 | <0.0001 |
| Hyperlipidemia | 4738 | 44.8 | 3685 | 34.8 | <0.0001 |
| Coronary artery disease | 813 | 7.69 | 681 | 6.44 | 0.0004 |
| Chronic obstructive pulmonary disease | 4326 | 40.9 | 3596 | 34.0 | <0.0001 |
| Follow-up time, year† | 5.68 (3.81) | 5.48 (3.84) | <0.0001 | ||
SD, standard deviation.
Diabetes mellitus included type 1 and type 2 diabetes mellitus.
*P-value using chi-square for the comparisons between with and without AMD.
†Average age and follow-up time using Wilcoxon rank-sum test for verification.
Table 2 demonstrates that there was a higher risk of developing AD in the AMD cohort than the control cohort (aHR = 1.23, 95% CI = 1.04–1.46), with incidences of 5.36 and 3.92 per 1,000 person-years in the AMD and non-AMD groups, respectively. Compared to the 50-64-year subgroup, the subgroups with individuals 65–79 years old and more than 80 years old have a significant 3.67 (95% CI = 2.69–5.01) and 7.53 (95% CI = 5.38–10.5) risk for AD. Among all of comorbidities, patients with cerebrovascular disease and chronic obstructive pulmonary disease tended to have a higher risk for the development of AD (aHR = 1.44, 95% CI = 1.19–1.73 and aHR = 1.20, 95% CI = 1.01–1.44). Compared to the patients without any comorbidities, patients with at least one comorbidity also have a significant 1.23 (95% CI = 1.04–1.47) risk for AD.
Table 2. Cox proportional HRs for risk of Alzheimer’s disease in patients with and without AMD, in different gender, age groups, and in patients with preexisting comorbidities.
| Variable | Alzheimer’s disease | Crude HR (95%CI) | Adjusted HR (95%CI) | ||
|---|---|---|---|---|---|
| Event | PY | IR | |||
| AMD | |||||
| No | 227 | 57939 | 3.92 | 1(reference) | 1(reference) |
| Yes | 322 | 60128 | 5.36 | 1.36 (1.15–1.62)*** | 1.23 (1.04–1.46)* |
| Gender | |||||
| Female | 249 | 59164 | 4.21 | 1(reference) | 1(reference) |
| Male | 300 | 58903 | 5.09 | 1.21 (1.02–1.43)* | 0.89 (0.74–1.07) |
| Age, years | |||||
| 50–64 | 47 | 38049 | 1.23 | 1(reference) | 1(reference) |
| 65–79 | 336 | 65212 | 5.15 | 4.22 (3.11–5.72)*** | 3.67 (2.69–5.01)*** |
| 80–100 | 166 | 14806 | 11.2 | 9.53 (6.88–13.2)*** | 7.53 (5.38–10.5)*** |
| P for trend | <0.0001 | <0.0001 | |||
| Comorbidity | |||||
| Osteoporosis | |||||
| No | 398 | 94104 | 4.23 | 1(reference) | 1(reference) |
| Yes | 151 | 23963 | 6.3 | 1.50 (1.24–1.81)*** | 1.22 (1.00–1.50) |
| Diabetes | |||||
| No | 306 | 72098 | 4.24 | 1(reference) | 1(reference) |
| Yes | 243 | 45969 | 5.29 | 1.25 (1.06–1.48)** | 1.06 (0.89–1.26) |
| Cirrhosis | |||||
| No | 368 | 79442 | 4.63 | 1(reference) | 1(reference) |
| Yes | 181 | 38625 | 4.69 | 1.01 (0.85–1.21) | -- |
| Cerebrovascular disease | |||||
| No | 359 | 93798 | 3.83 | 1(reference) | 1(reference) |
| Yes | 190 | 24269 | 7.83 | 2.08 (1.74–2.49)*** | 1.44 (1.19–1.73)*** |
| Chronic kidney disease | |||||
| No | 518 | 112987 | 4.58 | 1(reference) | 1(reference) |
| Yes | 31 | 5080 | 6.1 | 1.35 (0.94–1.94) | -- |
| Hypertension | |||||
| No | 132 | 42263 | 3.12 | 1(reference) | 1(reference) |
| Yes | 417 | 75804 | 5.5 | 1.77 (1.46–2.16)*** | 1.09 (0.88–1.34) |
| Hyperlipidemia | |||||
| No | 365 | 77597 | 4.7 | 1(reference) | 1(reference) |
| Yes | 184 | 40470 | 4.55 | 0.97 (0.81–1.16) | -- |
| Coronary artery disease | |||||
| No | 511 | 110964 | 4.61 | 1(reference) | 1(reference) |
| Yes | 38 | 7103 | 5.35 | 1.17 (0.84–1.62) | -- |
| Chronic obstructive pulmonary disease | |||||
| No | 295 | 78499 | 3.76 | 1(reference) | 1(reference) |
| Yes | 254 | 39568 | 6.42 | 1.73 (1.46–2.04)*** | 1.20 (1.01–1.44)* |
| Comorbidity amount | |||||
| 0 | 38 | 18111 | 2.09 | 1(reference) | 1(reference) |
| ≥1 | 511 | 99956 | 5.11 | 2.46 (1.77–3.43) | 1.23 (1.04–1.47)* |
PY, person-years; IR, incidence rate, per 1,000 person-years; HR, hazard ratio; CI, confidence interval.
HR adjusted for gender, age, osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, and chronic obstructive pulmonary disease.
*p<0.05
**p<0.01
***p<0.001.
Table 3 presents the risk for AD between patients with and without AMD stratified by gender, age, and comorbidities. Compared with the women without AMD, the AMD women had a significant higher risk of AD (aHR = 1.31, 95% CI = 1.04–1.66). And the younger patients were diagnosed with AMD, the more likely patients got AD (50–64 age group: aHR = 1.97, 95% CI = 1.04–3.73; 65–79 age group: aHR = 1.27, 95% CI = 1.02–1.58; 80–100 age group: aHR = 1.06, 95% CI = 0.78–1.45). Moreover, AMD patients with cirrhosis exhibited 1.50 (95% CI = 1.09–2.06) higher risk of AD compared with the non-AMD group. Comparing to without AMD cohort, the risk of AD for AMD in patients no matter with or without any comorbidities (aHR = 1.19, 95% CI = 1.00–1.42 and aHR = 2.19, 95% CI = 1.13–4.09) were also significantly higher.
Table 3. Incidence rates, hazard ratios, and confidence intervals of Alzheimer’s disease in patients with AMD stratified by gender, age and comorbidity.
| Variable | AMD | Crude HR (95%CI) | Adjusted HR (95%CI) | |||||
|---|---|---|---|---|---|---|---|---|
| No | Yes | |||||||
| Event | PY | IR | Event | PY | IR | |||
| Gender | ||||||||
| male | 107 | 29026 | 3.69 | 142 | 30138 | 4.71 | 1.27 (0.99-1.64) | 1.14 (0.88-1.47) |
| Female | 120 | 28913 | 4.15 | 180 | 29990 | 6 | 1.44 (1.14-1.82)** | 1.31 (1.04-1.66)* |
| Age, years | ||||||||
| 50-64 | 14 | 19125 | 0.73 | 33 | 18924 | 1.74 | 2.39 (1.28-4.47)** | 1.97 (1.04-3.73)* |
| 65-79 | 138 | 31826 | 4.33 | 198 | 33387 | 5.93 | 1.36 (1.09-1.69)** | 1.27 (1.02-1.58)* |
| 80-100 | 75 | 6988 | 10.7 | 91 | 7817 | 11.6 | 1.08 (0.79-1.46) | 1.06 (0.78-1.45) |
| Comorbidity | ||||||||
| Osteoporosis | ||||||||
| No | 168 | 47959 | 3.5 | 230 | 46144 | 4.98 | 1.42 (1.16-1.73)*** | 1.30 (1.06-1.59)** |
| Yes | 59 | 9980 | 5.91 | 92 | 13984 | 6.58 | 1.11 (0.80-1.55) | 1.06 (0.76-1.47) |
| Diabetes | ||||||||
| No | 131 | 38743 | 3.38 | 175 | 33355 | 5.25 | 1.55 (1.23-1.94)*** | 1.33 (1.06-1.68)* |
| Yes | 96 | 19196 | 5 | 147 | 26773 | 5.49 | 1.09 (0.84-1.41) | 1.09 (0.84-1.41) |
| Cirrhosis | ||||||||
| No | 171 | 41807 | 4.09 | 197 | 37636 | 5.23 | 1.28 (1.04-1.57)* | 1.13 (0.92-1.40) |
| Yes | 56 | 16132 | 3.47 | 125 | 22492 | 5.56 | 1.60 (1.16-2.19)** | 1.50 (1.09-2.06)* |
| Cerebrovascular disease | ||||||||
| No | 150 | 47548 | 3.15 | 209 | 46250 | 4.52 | 1.42 (1.15-1.76)*** | 1.29 (1.04-1.60)* |
| Yes | 77 | 10391 | 7.41 | 113 | 13878 | 8.14 | 1.10 (0.82-1.48) | 1.11 (0.83-1.48) |
| Chronic kidney disease | ||||||||
| No | 214 | 55876 | 3.83 | 304 | 57111 | 5.32 | 1.38 (1.16-1.65)*** | 1.24 (1.03-1.48)* |
| Yes | 13 | 2063 | 6.3 | 18 | 3017 | 5.97 | 0.94 (0.46-1.93) | 1.10 (0.53-2.26) |
| Hypertension | ||||||||
| No | 60 | 23660 | 2.54 | 72 | 18603 | 3.87 | 1.52 (1.07-2.14)* | 1.44 (1.02-2.04)* |
| Yes | 167 | 34279 | 4.87 | 250 | 41525 | 6.02 | 1.23 (1.01-1.50)* | 1.17 (0.96-1.43) |
| Hyperlipidemia | ||||||||
| No | 164 | 41081 | 3.99 | 201 | 36515 | 5.5 | 1.37 (1.12-1.69)** | 1.22 (0.99-1.50) |
| Yes | 63 | 16858 | 3.74 | 121 | 23613 | 5.12 | 1.36 (1.00-1.85)* | 1.29 (0.95-1.75) |
| Coronary artery disease | ||||||||
| No | 210 | 54944 | 3.82 | 301 | 56020 | 5.37 | 1.40 (1.17-1.67)*** | 1.27 (1.06-1.52)** |
| Yes | 17 | 2995 | 5.68 | 21 | 4108 | 5.11 | 0.91 (0.48-1.73) | 0.83 (0.43-1.58) |
| Chronic obstructive pulmonary disease | ||||||||
| No | 124 | 40896 | 3.03 | 171 | 37603 | 4.55 | 1.49 (1.18-1.88)*** | 1.35 (1.07-1.71)* |
| Yes | 103 | 17043 | 6.04 | 151 | 22525 | 6.7 | 1.11 (0.86-1.42) | 1.09 (0.84-1.40) |
| Comorbidity amount | ||||||||
| 0 | 18 | 11915 | 1.51 | 20 | 6196 | 3.22 | 2.06 (1.09-3.91)* | 2.15 (1.13-4.09)* |
| >1 | 209 | 46024 | 4.54 | 302 | 53932 | 5.59 | 1.23 (1.03-1.47)* | 1.19 (1.00-1.42)* |
PY, person-years; IR, incidence rate, per 1,000 person-years; HR, hazard ratio; CI, confidence interval.
HR adjusted for gender, age, osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease and chronic obstructive pulmonary disease.
*p<0.05
**p<0.01
***p<0.001.
Table 4 presents the incidence rate of AD among different types of AMD. There were no statistically significant differences in the risk of AD between with and without macular degeneration (ICD-9-CM code: 362.50), nonexudative senile macular degeneration (ICD-9-CM code: 362.51), and exudative senile macular degeneration (ICD-9-CM code: 362.52) patients.
Table 4. Incidence rates, hazard ratios, and confidence intervals of Alzheimer’s disease among different type of AMD.
| Variable | Alzheimer’s disease | Crude HR (95%CI) | Adjusted HR (95%CI) | ||
|---|---|---|---|---|---|
| Event | PY | IR | |||
| Type of AMD | |||||
| ICD-9-CM code: 362.50 | |||||
| No | 279 | 65057 | 4.28 | 1(reference) | 1(reference) |
| Yes | 270 | 53010 | 5.09 | 1.18 (1.00–1.40)* | 1.11 (0.94–1.32) |
| ICD-9-CM code: 362.51 | |||||
| No | 493 | 109339 | 4.50 | 1(reference) | 1(reference) |
| Yes | 56 | 8728 | 6.41 | 1.41 (1.07–1.86)* | 1.30 (0.85–1.49) |
| ICD-9-CM code: 362.52 | |||||
| No | 515 | 112435 | 4.58 | 1(reference) | 1(reference) |
| Yes | 34 | 5632 | 6.03 | 1.31 (0.93–1.86) | 1.16 (0.82–1.64) |
PY, person-years; IR, incidence rate, per 1,000 person-years; HR, hazard ratio; CI, confidence interval.
*p<0.05.
The Kaplan–Meier plot of the cumulative incidence of Alzheimer’s disease in AMD and comparison cohort is depicted in Fig 1. After 11 years of follow-up, the AMD group had a significantly higher cumulative proportion of AD patients than did the non-AMD group (log-rank test (p = 0.003)). Fig 2 presents that there was a considerably different cumulative incidence of among each age group (log-rank p <0.0001).
Fig 1. Kaplan-Meier plot of the cumulative incidence of Alzheimer’s disease in patients with and without AMD.
Fig 2. Kaplan-Meier plot of the cumulative incidence of Alzheimer’s disease in each age group.
Discussion
This large-scale, nationwide, retrospective cohort study showed that patients with AMD exhibited a 1.23-fold higher risk of developing AD (aHR = 1.23, 95% CI = 1.04–1.46) than patients without AMD. Old age, cerebrovascular disease, and chronic obstructive pulmonary disease were also risk factors for AD. AMD patients who were female, younger age and with cirrhosis had a significant higher risk of developing AD.
Several publications have documented that AMD is associated with increased risk of AD or cognitive impairment. In 2006, the Blue Mountains Eye Study showed that people with late AMD were associated with lower Mini-Mental State Examination scores than people without AMD [34]. A cross-sectional study reported that AD frequency was significantly increased in the AMD group. The nonexudative AMD subtype was associated with worse cognitive function than the exudative AMD subtype [35]. Similarly, the population-based cohort study in Taiwan by Tsai suggested that patients with AMD had a greater risk of developing AD, although the nonexudative AMD subtype alone showed a conventional level of significance in stratified analysis [36]. However, neither the nonexudative nor the exudative AMD subtype was a significant risk factor for AD in our stratified analysis. The follow-up duration in our study is longer than that of Tsai (2000–2012 vs. 2001–2009), which may contribute to this finding. In a recent paper by Choi, AMD was associated with a higher risk of AD, even after considering lifestyle behaviors, including smoking, alcohol intake, and physical activity [37]. In contrast, the results obtained by Keenan et al. suggested that there is no positive association between AMD and AD. However, in England, most patients with AMD were admitted for receiving intravitreal anti-vascular endothelial growth factor therapy, which is the standard treatment for exudative AMD [30].
Aging is the primary risk factor for both AD and AMD [38]. Oxidative stress is considered to be an imbalance between free radicals and antioxidants, which is the fundamental mechanism contributing to the aging process [39]. Previous studies indicated that oxidative stress may be the common underlying pathological mechanism between AD and AMD [17]. Researchers have found that the levels of lipid peroxidation end products, oxidized proteins, and advanced glycation end products are increased in AD [40, 41]. Likewise, the elevation of oxidative stress was observed in the retina of patients with AMD [42, 43]. In 2011, a study showed that oxidative stress upregulated β-secretase and γ-secretase activities, resulting in increased Aβ production [44]. Common pathogenic pathways could explain the association between AMD and AD.
The strength of this study is the use of NHIRD, a nationwide population-based database, which covers over 99% of medical claims data of citizens in Taiwan, reducing the likelihood of selection and participation bias. However, some limitations should be noted. First, some confounding variables were unavailable in NHIRD. Smoking habit, alcohol consumption, body mass index, physical activity, and family history of AD could not be adjusted in the data analysis. Second, NHIRD lacks imaging findings, neuropsychological assessment results, and laboratory data. Third, AD, AMD, and additional comorbidities cases were identified using ICD-9-CM codes. Same as all claims databases, the accuracy of diagnosis codes is still a concern. However, several studies have validated the positive predictive value of the diagnostic ICD9-CM codes for common diseases, such as ischemic stroke, hypertension, diabetes and all cancers [31–33]. Finally, AD and AMD are not usually diagnosed in the early stages, which could lead to misclassification bias in our study.
In conclusion, our study suggests that patients with AMD have a higher risk of AD than people without AMD. The exact pathological factors are still poorly understood, and further studies need to be conducted to explore the underlying mechanism between AD and AMD.
Supporting information
(DOCX)
Acknowledgments
We would like to thank all the participants for their enthusiastic participation in this study.
Data Availability
The dataset used in this study was obtained from the National Health Insurance Administration of Taiwan and is held by the Taiwan Ministry of Health and Welfare (MOHW). The MOHW must approve applications to access this data. Any researcher interested in accessing this dataset can submit an application form to the MOWH requesting access. Please contact the staff at MOHW (email: stcarolwu@mohw.gov.tw) for further assistance. The authors confirm that they had no special access privileges others would not have.
Funding Statement
This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW109-TDU-B-212-114004), MOST Clinical Trial Consortium for Stroke (MOST 109-2321-B-039-002), China Medical University Hospital (DMR-104-063, DMR-105-087, DMR-106-084), China Medical University, Taichung, Taiwan (CMU108-MF-40; CMU109-MF-62) Tseng-Lien Lin Foundation, Taichung, Taiwan.
References
- 1.Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer’s Disease. Biomed Res Int. 2016;2016:2589276. Epub 2016/08/23. 10.1155/2016/2589276 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Sub-cellular biochemistry. 2012;65:329–52. Epub 2012/12/12. 10.1007/978-94-007-5416-4_14 . [DOI] [PubMed] [Google Scholar]
- 3.Octave J. Alzheimer disease: cellular and molecular aspects. Bulletin et memoires de l’Academie royale de medecine de Belgique. 2005;160(10–12):445–9; discussion 50. [PubMed] [Google Scholar]
- 4.Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1–18. Epub 2015/07/08. 10.1016/j.npep.2015.06.008 . [DOI] [PubMed] [Google Scholar]
- 5.Korczyn AD. The amyloid cascade hypothesis. Alzheimer’s & dementia. 2008;4(3):176–8. 10.1016/j.jalz.2007.11.008 [DOI] [PubMed] [Google Scholar]
- 6.Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular medicine. 2010;12(1):1–12. 10.1007/s12017-009-8104-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annual review of neuroscience. 2011;34:185–204. 10.1146/annurev-neuro-061010-113613 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Shankar GM, Walsh DM. Alzheimer’s disease: synaptic dysfunction and Aβ. Molecular neurodegeneration. 2009;4(1):48. 10.1186/1750-1326-4-48 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774–. 10.1126/science.1197623 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the Epidemiology of Age-Related Macular Degeneration. Asia Pac J Ophthalmol (Phila). 2017;6(6):493–7. Epub 2017/09/15. 10.22608/APO.2017251 . [DOI] [PubMed] [Google Scholar]
- 11.Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. The Lancet. 2012;379(9827):1728–38. [DOI] [PubMed] [Google Scholar]
- 12.Al Gwairi O, Thach L, Zheng W, Osman N, Little PJ. Cellular and molecular pathology of age-related macular degeneration: potential role for proteoglycans. Journal of ophthalmology. 2016;2016. 10.1155/2016/2913612 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, et al. The potential role of amyloid β in the pathogenesis of age-related macular degeneration. The Journal of clinical investigation. 2005;115(10):2793–800. 10.1172/JCI24635 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ashok A, Singh N, Chaudhary S, Bellamkonda V, Kritikos AE, Wise AS, et al. Retinal Degeneration and Alzheimer’s Disease: An Evolving Link. International Journal of Molecular Sciences. 2020;21(19):7290. 10.3390/ijms21197290 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Dentchev T, Milam AH, Lee VM-Y, Trojanowski JQ, Dunaief JL. Amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. American journal of ophthalmology. 2003;136(4):787–. [PubMed] [Google Scholar]
- 16.Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Molecular vision. 2003;9:184–90. Epub 2003/05/24. . [PubMed] [Google Scholar]
- 17.Cerman E, Eraslan M, Cekic O. Age-related macular degeneration and Alzheimer disease. Turk J Med Sci. 2015;45(5):1004–9. Epub 2016/01/08. 10.3906/sag-1406-146 . [DOI] [PubMed] [Google Scholar]
- 18.Agostinho P, A Cunha R, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Current pharmaceutical design. 2010;16(25):2766–78. 10.2174/138161210793176572 [DOI] [PubMed] [Google Scholar]
- 19.Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, et al. Oxidative damage–induced inflammation initiates age-related macular degeneration. Nature medicine. 2008;14(2):194–8. 10.1038/nm1709 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, et al. An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes research and clinical practice. 2017;124:41–7. 10.1016/j.diabres.2016.10.024 [DOI] [PubMed] [Google Scholar]
- 21.Chen X, Rong SS, Xu Q, Tang FY, Liu Y, Gu H, et al. Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. PloS one. 2014;9(9):e108196. 10.1371/journal.pone.0108196 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Durazzo TC, Mattsson N, Weiner MW, Initiative AsDN. Smoking and increased Alzheimer’s disease risk: a review of potential mechanisms. Alzheimer’s & Dementia. 2014;10:S122–S45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Neuner B, Komm A, Wellmann J, Dietzel M, Pauleikhoff D, Walter J, et al. Smoking history and the incidence of age-related macular degeneration—results from the Muenster Aging and Retina Study (MARS) cohort and systematic review and meta-analysis of observational longitudinal studies. Addictive behaviors. 2009;34(11):938–47. 10.1016/j.addbeh.2009.05.015 [DOI] [PubMed] [Google Scholar]
- 24.Williams MA, McKay GJ, Carson R, Craig D, Silvestri G, Passmore P. Age-Related Macular Degeneration–Associated Genes in Alzheimer Disease. The American Journal of Geriatric Psychiatry. 2015;23(12):1290–6. 10.1016/j.jagp.2015.06.005 [DOI] [PubMed] [Google Scholar]
- 25.Butler JM, Sharif U, Ali M, McKibbin M, Thompson JP, Gale R, et al. A missense variant in CST3 exerts a recessive effect on susceptibility to age-related macular degeneration resembling its association with Alzheimer’s disease. Human genetics. 2015;134(7):705–15. 10.1007/s00439-015-1552-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Wong TY, Klein R, Nieto FJ, Moraes SA, Mosley TH, Couper DJ, et al. Is early age-related maculopathy related to cognitive function? The Atherosclerosis Risk in Communities Study. American journal of ophthalmology. 2002;134(6):828–35. 10.1016/s0002-9394(02)01672-0 [DOI] [PubMed] [Google Scholar]
- 27.Pham TQ, Kifley A, Mitchell P, Wang JJ. Relation of age-related macular degeneration and cognitive impairment in an older population. Gerontology. 2006;52(6):353–8. 10.1159/000094984 [DOI] [PubMed] [Google Scholar]
- 28.Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT. Is age-related maculopathy associated with Alzheimer’s disease?: the Rotterdam Study. American journal of epidemiology. 1999;150(9):963–8. 10.1093/oxfordjournals.aje.a010105 [DOI] [PubMed] [Google Scholar]
- 29.Rong SS, Lee BY, Kuk AK, Yu XT, Li SS, Li J, et al. Comorbidity of dementia and age-related macular degeneration calls for clinical awareness: a meta-analysis. British Journal of Ophthalmology. 2019;103(12):1777–83. 10.1136/bjophthalmol-2018-313277 [DOI] [PubMed] [Google Scholar]
- 30.Keenan TD, Goldacre R, Goldacre MJ. Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol. 2014;132(1):63–8. Epub 2013/11/16. 10.1001/jamaophthalmol.2013.5696 . [DOI] [PubMed] [Google Scholar]
- 31.Hsieh C-Y, Chen C-H, Li C-Y, Lai M-L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. Journal of the Formosan Medical Association. 2015;114(3):254–9. 10.1016/j.jfma.2013.09.009 [DOI] [PubMed] [Google Scholar]
- 32.Sung S-F, Hsieh C-Y, Lin H-J, Chen Y-W, Yang Y-HK, Li C-Y. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. International journal of cardiology. 2016;215:277–82. 10.1016/j.ijcard.2016.04.069 [DOI] [PubMed] [Google Scholar]
- 33.Kao WH, Hong JH, See LC, Yu HP, Hsu JT, Chou IJ, et al. Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan. Pharmacoepidemiology and drug safety. 2018;27(10):1060–6. 10.1002/pds.4267 [DOI] [PubMed] [Google Scholar]
- 34.Hong T, Mitchell P, Burlutsky G, Liew G, Wang JJ. Visual Impairment, Hearing Loss and Cognitive Function in an Older Population: Longitudinal Findings from the Blue Mountains Eye Study. PloS one. 2016;11(1):e0147646. Epub 2016/01/26. 10.1371/journal.pone.0147646 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Seden D, Alime G, Kadir D, Serpil D, Levent T, Ozlem T. Is Alzheimer disease related to age-related macular degeneration? Turk J Med Sci. 2015;45(5):1115–21. Epub 2016/01/08. 10.3906/sag-1406-135 . [DOI] [PubMed] [Google Scholar]
- 36.Tsai DC, Chen SJ, Huang CC, Yuan MK, Leu HB. Age-Related Macular Degeneration and Risk of Degenerative Dementia among the Elderly in Taiwan: A Population-Based Cohort Study. Ophthalmology. 2015;122(11):2327–35 e2. Epub 2015/09/05. 10.1016/j.ophtha.2015.07.033 . [DOI] [PubMed] [Google Scholar]
- 37.Choi S, Jahng WJ, Park SM, Jee D. Association of Age-Related Macular Degeneration on Alzheimer or Parkinson Disease: A Retrospective Cohort Study. Am J Ophthalmol. 2020;210:41–7. Epub 2019/11/13. 10.1016/j.ajo.2019.11.001 . [DOI] [PubMed] [Google Scholar]
- 38.Biscetti L, Luchetti E, Vergaro A, Menduno P, Cagini C, Parnetti L. Associations of Alzheimer’s disease with macular degeneration. Frontiers in bioscience (Elite edition). 2017;9:174–91. 10.2741/e794 [DOI] [PubMed] [Google Scholar]
- 39.Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: harms and benefits for human health. Oxidative medicine and cellular longevity. 2017;2017. 10.1155/2017/8416763 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Chen Z, Zhong C. Oxidative stress in Alzheimer’s disease. Neuroscience bulletin. 2014;30(2):271–81. 10.1007/s12264-013-1423-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer’s disease. Biomedical reports. 2016;4(5):519–22. 10.3892/br.2016.630 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bellezza I. Oxidative stress in age-related macular degeneration: Nrf2 as therapeutic target. Frontiers in pharmacology. 2018;9:1280. 10.3389/fphar.2018.01280 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Beatty S, Koh H-H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Survey of ophthalmology. 2000;45(2):115–34. 10.1016/s0039-6257(00)00140-5 [DOI] [PubMed] [Google Scholar]
- 44.Mouton-Liger F, Paquet C, Dumurgier J, Bouras C, Pradier L, Gray F, et al. Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2α pathway. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2012;1822(6):885–96. 10.1016/j.bbadis.2012.01.009 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
(DOCX)
Data Availability Statement
The dataset used in this study was obtained from the National Health Insurance Administration of Taiwan and is held by the Taiwan Ministry of Health and Welfare (MOHW). The MOHW must approve applications to access this data. Any researcher interested in accessing this dataset can submit an application form to the MOWH requesting access. Please contact the staff at MOHW (email: stcarolwu@mohw.gov.tw) for further assistance. The authors confirm that they had no special access privileges others would not have.